Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized
by gradually failing heart with detrimental cardiac remodelings, such as fibrosis and diastolic
and systolic dysfunction, which is not directly attributable to coronary artery disease. Insulin resistance
and resulting hyperglycemia is the main trigger involved in the initiation of diabetic cardiomyopathy.
There is a constellation of many pathophysiological events, such as lipotoxicity, oxidative stress, inflammation,
inappropriate activation of the renin-angiotensin-aldosterone system, dysfunctional immune
modulation promoting increased rate of cardiac cell injury, apoptosis, and necrosis, which ultimately
culminates into interstitial fibrosis, cardiac stiffness, diastolic dysfunction, initially, and later
systolic dysfunction too. These events finally lead to clinical heart failure of DCM. Herein, The pathophysiology
of DCM is briefly discussed. Furthermore, potential therapeutic strategies currently used
for DCM are also briefly mentioned.